tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

AGMB.NB

AGMB
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
12.870USD
+0.115+0.90%
์ข…๊ฐ€ย 07-31 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
633.82M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ์ฐจํŠธ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

+0.90%

5์ผ

+2.88%

1๊ฐœ์›”

+1.74%

6๊ฐœ์›”

0.00%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

0.00%

1๋…„

0.00%

ํ•ต์‹ฌ ์ˆ˜์น˜
12.760์‹œ๊ฐ€
13.000์ตœ๊ณ ๊ฐ€
54.09K๊ฑฐ๋ž˜๋Ÿ‰
์†์‹คP/E TTM
์†์‹ค๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.11%ํšŒ์ „์œจ
12.755์ „์ผ ์ข…๊ฐ€
12.255์ตœ์ €๊ฐ€
552.73K๋งค์ถœ์•ก
--์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
4.10P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
--ROA
17.45352์ฃผ ์ตœ๊ณ ๊ฐ€
1.15๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
--์ˆœ์ด์ต
48.74M์ฃผ์‹
-1.0927์ฃผ๋‹น์ˆœ์ด์ต
--๋ฒ ํƒ€
--ROE
9.00052์ฃผ ์ตœ์ €๊ฐ€
5.84%๋ณ€๋™ ํญ
--์ด ์ด์ต๋ฅ 
633.82M์‹œ๊ฐ€์ด์•ก
-0.94๋ณด์ƒ/์œ„ํ—˜
6.01%์œ„ํ—˜๋ฅ 

AGMB.NB ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์˜ˆ์ƒ๎˜

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

6 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
33.200
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+157.96%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

496
์ด๊ณ„
6
์ค‘๊ฐ„
7
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
AGMB.NB
AGMB
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99

์ง€ํ‘œ๎˜

์ง€ํ‘œ
๋งค๋„(1)
์ค‘๋ฆฝ(3)
๋งค์ˆ˜(3)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
0.008
๋งค์ˆ˜
RSI(14)
53.979
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
69.889
์ค‘๋ฆฝ
ATR(14)
0.999
์ €๋ณ€๋™์„ฑ
CCI(14)
77.503
์ค‘๋ฆฝ
Williams %R
24.943
๋งค์ˆ˜
TRIX(12,20)
0.060
๋งค๋„
StochRSI(14)
100.000
๋งค์ˆ˜
์ด๋™ ํ‰๊ท 
๋งค๋„(0)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(6)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
12.615
๋งค์ˆ˜
MA10
12.378
๋งค์ˆ˜
MA20
12.538
๋งค์ˆ˜
MA50
11.930
๋งค์ˆ˜
MA100
11.748
๋งค์ˆ˜
MA200
12.354
๋งค์ˆ˜

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

AGMB.NB ์ •๋ณด๎˜

Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
์ข…๋ชฉ ์ฝ”๋“œ AGMB
ํšŒ์‚ฌAGMB.NB
CEOKnotnerus (Tim)
์›น์‚ฌ์ดํŠธhttps://agomab.com/

์ฃผ์ฃผ๎˜

์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Fidelity Management & Research Company LLC
9.90%
Pontifax Venture Capital
6.71%
Sanofi SA
5.65%
EQT Life Sciences
2.28%
abrdn Inc.
1.44%
๊ธฐํƒ€
74.02%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

AGMB.NB(AGMB)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
AGMB.NB(AGMB)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 12.87์ž…๋‹ˆ๋‹ค.

AGMB.NB์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
AGMB.NB์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” AGMB์ž…๋‹ˆ๋‹ค.

AGMB.NB์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
AGMB.NB์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 17.45์ž…๋‹ˆ๋‹ค.

AGMB.NB์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
AGMB.NB์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 9.00์ž…๋‹ˆ๋‹ค.

AGMB.NB์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
AGMB.NB์˜ ์‹œ๊ฐ€์ด์•ก์€ 633.82M์ž…๋‹ˆ๋‹ค.

AGMB.NB(AGMB)์˜ ํ˜„์žฌ ํˆฌ์ž ๋“ฑ๊ธ‰์€ ๋งค์ˆ˜, ๋ณด์œ , ๋งค๋„ ์ค‘ ์–ด๋–ค๊ฐ€์š”?

๎™Œ
์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์— ๋”ฐ๋ฅด๋ฉด, AGMB.NB(AGMB)๋Š” ์ „๋ฐ˜์ ์ธ ํ‰๊ฐ€์—์„œ ๊ตฌ์ž…ํ•˜๋‹ค ๋“ฑ๊ธ‰์„ ๋ฐ›๊ณ  ์žˆ์œผ๋ฉฐ, ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” 33.20์ž…๋‹ˆ๋‹ค.

AGMB.NB(AGMB)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
AGMB.NB(AGMB)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ -1.51์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ